RxDoctor Payments Data

Jianping Zhou, PA

Physician Assistant · Pasadena, MDNPI 1881636744

Payments from drug & device makers

$4,131in general payments, 2019–2025

Across 127 payments — averaging $32.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$360
  • Novo Nordisk$326
  • Lilly USA, LLC$320
  • Dexcom, Inc.$237
  • GSK$224
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,117100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,131 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$132,553
Medicare patients
441
Services billed
1,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$59,918
JardianceEmpagliflozin27$37,160
EliquisApixaban38$29,505
TrulicityDulaglutide13$25,316
JanuviaSitagliptin Phosphate18$24,737
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$21,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,360
TradjentaLinagliptin13$14,963
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,027
Praluent PenAlirocumab14$6,487
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,109
Novolog FlexpenInsulin Aspart22$5,011
Atorvastatin Calcium274$4,243
Metoprolol Succinate170$3,126
SymbicortBudesonide/Formoterol Fumarate11$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$326$59,91857 claims
Boehringer IngelheimJardiance, Tradjenta$185$52,12440 claims
PfizerEliquis$223$29,50538 claims
GSKTrelegy Ellipta, Anoro Ellipta$224$26,38641 claims
Lilly USA, LLCTrulicity$320$25,31613 claims
MerckJanuvia$111$24,73718 claims
AstraZenecaSymbicort$360$2,59811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →